These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 16281888)
1. Issues in regulatory guidelines for data monitoring committees. DeMets D; Califf R; Dixon D; Ellenberg S; Fleming T; Held P; Julian D; Kaplan R; Levine R; Neaton J; Packer M; Pocock S; Rockhold F; Seto B; Siegel J; Snapinn S; Stump D; Temple R; Whitley R Clin Trials; 2004; 1(2):162-9. PubMed ID: 16281888 [TBL] [Abstract][Full Text] [Related]
2. On the independence of data monitoring committee in adaptive design clinical trials. Chow SC; Corey R; Lin M J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119 [TBL] [Abstract][Full Text] [Related]
3. Issues in data monitoring and interim analysis of trials. Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA; Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038 [TBL] [Abstract][Full Text] [Related]
4. Playing safe and preserving integrity: making the FDA model work. Wittes J Stat Med; 2004 May; 23(10):1523-5. PubMed ID: 15122731 [TBL] [Abstract][Full Text] [Related]
6. The independent statistician for data monitoring committees. DeMets DL; Fleming TR Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729 [TBL] [Abstract][Full Text] [Related]
7. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting? Bryant J Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728 [TBL] [Abstract][Full Text] [Related]
8. The changing landscape of data monitoring committees-Perspectives from regulators, members, and sponsors. Bhattacharyya A; Gallo P; Crisp A; LaVange L; Molenberghs G; Pétavy F; Seltzer J Biom J; 2019 Sep; 61(5):1232-1241. PubMed ID: 30589102 [TBL] [Abstract][Full Text] [Related]
9. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative. Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947 [TBL] [Abstract][Full Text] [Related]
10. Exploring the role and function of trial steering committees: results of an expert panel meeting. Harman NL; Conroy EJ; Lewis SC; Murray G; Norrie J; Sydes MR; Lane JA; Altman DG; Baigent C; Bliss JM; Campbell MK; Elbourne D; Evans S; Sandercock P; Gamble C Trials; 2015 Dec; 16():597. PubMed ID: 26715378 [TBL] [Abstract][Full Text] [Related]
11. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees. ; Dixon DO; Freedman RS; Herson J; Hughes M; Kim K; Silverman MH; Tangen CM Clin Trials; 2006; 3(3):314-9. PubMed ID: 16895048 [TBL] [Abstract][Full Text] [Related]
12. Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. Filippatos GS; de Graeff P; Bax JJ; Borg JJ; Cleland JG; Dargie HJ; Flather M; Ford I; Friede T; Greenberg B; Henon-Goburdhun C; Holcomb R; Horst B; Lekakis J; Mueller-Velten G; Papavassiliou AG; Prasad K; Rosano GM; Severin T; Sherman W; Stough WG; Swedberg K; Tavazzi L; Tousoulis D; Vardas P; Ruschitzka F; Anker SD Eur J Heart Fail; 2017 Apr; 19(4):449-456. PubMed ID: 28271595 [TBL] [Abstract][Full Text] [Related]
13. Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting. Lilienfeld DE Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):381-5. PubMed ID: 15170767 [TBL] [Abstract][Full Text] [Related]
14. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations. Rockhold FW; Enas GG Stat Med; 1993 Mar; 12(5-6):471-9. PubMed ID: 8493425 [TBL] [Abstract][Full Text] [Related]
15. Understanding the functions and operations of data monitoring committees: Survey and focus group findings. Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056 [TBL] [Abstract][Full Text] [Related]
16. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership? Ellenberg SS; George SL Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727 [TBL] [Abstract][Full Text] [Related]
17. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. Lachin JM Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730 [TBL] [Abstract][Full Text] [Related]
18. The impact of escalating regulatory requirements on the conduct of clinical research. Gordon BG; Kessinger A; Mann SL; Prentice ED Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237 [TBL] [Abstract][Full Text] [Related]
19. "You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study. Snowdon C; Brocklehurst P; Tasker RC; Ward Platt M; Elbourne D PLoS One; 2018; 13(7):e0201037. PubMed ID: 30048484 [TBL] [Abstract][Full Text] [Related]
20. Data monitoring in randomized controlled trials: surveys of recent practice and policies. Clemens F; Elbourne D; Darbyshire J; Pocock S; Clin Trials; 2005; 2(1):22-33. PubMed ID: 16279576 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]